prostatex 0,5 mg zachte caps.
apotex europe b.v. - dutasteride 0,5 mg - capsule, zacht - 0,5 mg - dutasteride 0.5 mg - dutasteride
provenge
dendreon uk ltd - autologe mononucleaire perifere bloedcellen inclusief minimaal 50 miljoen autologe cd54 + cellen geactiveerd met prostaat zure fosfatase granulocyt-macrofaag koloniestimulerende factor - prostaatnoplasma - andere immunostimulantia - provenge is geïndiceerd voor de behandeling van asymptomatische of minimaal symptomatische metastatische (niet-viscerale) castraatresistente prostaatkanker bij mannelijke volwassenen bij wie chemotherapie nog niet klinisch geïndiceerd is.
urorec
recordati ireland ltd - silodosin - prostaathyperplasie - urologica - behandeling van de tekenen en symptomen van goedaardige prostaathyperplasie (bph).
silodyx
recordati ireland ltd - silodosin - prostaathyperplasie - urologica - behandeling van de tekenen en symptomen van goedaardige prostaathyperplasie (bph).
silodosin recordati
recordati ireland ltd - silodosin - prostaathyperplasie - urologicals, alfa-adrenoreceptor antagonisten - de behandeling van de tekenen en symptomen van goedaardige prostaatvergroting (bph) bij volwassen mannen.
mictonorm forte 45 mg harde caps. verl. afgifte
consilient health ltd. - propiverinehydrochloride 45 mg - eq. propiverine 40,92 mg - capsule met verlengde afgifte, hard - 45 mg - propiverinehydrochloride 45 mg - propiverine
pylclari
curium pet france - piflufolastat (18f) - prostaatnoplasma - diagnostische radiofarmaceutica - dit geneesmiddel is uitsluitend voor diagnostisch gebruik. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).
zytiga
janssen-cilag international n.v. - abirateronacetaat - prostaatnoplasma - endocriene therapie - zytiga is aangegeven met prednison of prednisolon voor:de behandeling van gemetastaseerd castratie resistente prostaatkanker bij volwassen mannen die asymptomatisch of mild symptomatisch na de mislukking van androgeen deprivatie therapie bij wie chemotherapie is nog niet klinisch indicatedthe behandeling van gemetastaseerd castratie resistente prostaatkanker bij volwassen mannen bij wie de ziekte is gevorderd op of na een docetaxel gebaseerde chemotherapie regime.
abiraterone accord
accord healthcare s.l.u. - abirateronacetaat - prostaatnoplasma - endocriene therapie - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
abiraterone mylan
mylan ireland limited - abirateronacetaat - prostaatnoplasma - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.